BioSpace News Archive

ZSFab, Inc., a 3D-printing medical device company, is proud to announce that the ZSFab Cervical Interbody System has been successfully used in its first clinical case in the United States with Dr. Fernando Villamil, Orthopaedic Surgeon at the Center for Orthopedic Reconstruction and Excellence (CORE) Hospital in Jenks, Oklahoma.

RELIEF THERAPEUTICS Holding SA announced that Nermeen Varawalla, M.D., Ph.D., chief medical officer, will depart the Company in the second quarter of 2023 to pursue other opportunities.

Avacta Group plc, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the first-in-human phase I trial of AVA6000.

Pharvaris, a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema attacks, reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update.

Arch Therapeutics, Inc. announced that the Centers for Medicare and Medicaid Services Level II Healthcare Common Procedure Coding System code dedicated to the Company’s AC5® Advanced Wound System went into effect on April 1, 2023.

Oculis Holding AG announces that members of management will be participating in the following April investor conferences.

Proxygen, a leader in the discovery and development of molecular glue degraders, announced today a multi-year research collaboration and license agreement with Merck & Co Inc., Rahway, N.J., USA, known as MSD outside the U.S. and Canada, to jointly identify and develop molecular glue degraders against multiple therapeutic targets.

Societal CDMO, Inc., a contract development and manufacturing organization, announced that it has been selected by Longboard Pharmaceuticals, Inc. to provide CDMO services.

Immunic, Inc. reported positive data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset, vidofludimus calcium, in patients with moderate-to-severe ulcerative colitis .

CareDx, Inc. and Miromatrix Medical Inc. announced an exclusive partnership aimed at advancing the next wave of innovation using fully transplantable human bioengineered organs.